Evidence map›Paper›PMID 35990020›Full record

ArticleArhiv za farmaciju2021

Endocrine-disrupting activity of mancozeb.

Anatoly Skalny, Michael Aschner, Monica Paoliello, Abel Santamaria, Natalia Nikitina, Vladimir Rejniuk, Yueming Jiang, João Rocha, Alexey Tinkov

Open access · diamondAbstract read
In one paragraph

Article in Arhiv za farmaciju, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Impacts ofOpen veterinary journal · 2025
    Article
  6. The Potential Effect of Bualuang (WhiteLife (Basel, Switzerland) · 2024
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 5 countries.

Anatoly SkalnyIM Sechenov First Moscow State Medical University, Moscow 119146, Russia.
Michael AschnerIM Sechenov First Moscow State Medical University, Moscow 119146, Russia.
Monica PaolielloDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Abel SantamariaLaboratorio de Aminoácidos Excitadores/Laboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía, Mexico City 14269, Mexico.
Natalia NikitinaIM Sechenov First Moscow State Medical University, Moscow 119146, Russia.
Vladimir RejniukGolikov Research Center of Toxicology, Saint Petersburg 192019, Russia.
Yueming JiangDepartment of Toxicology,School of Public Health, Guangxi Medical University, Nanning 530021, China.
João RochaDepartamento de Bioquímica e Biologia Molecular, CCNE, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil.
Alexey TinkovPeoples' Friendship University of Russia (RUDN University), Moscow 117198, Russia.
Albert Einstein College of Medicine · USSechenov University · RUGuangxi Medical University · CNInstituto Nacional de Neurología y Neurocirugía · MXOrenburg State University · RUUniversidade Federal de Santa Maria · BR

Funding

Mechanisms of Manganese NeurotoxicityR01ES010563 · NIEHS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Michael Aschner, Aaron B Bowman · 2001 to 2026
$11.9M
NIEHS NIH HHS R01 ES010563
6 · The paper itself

Abstract

The objective of the present study was to review the existing data on the mechanisms involved in the endocrine disrupting activity of mancozeb (MCZ) in its main targets, including thyroid and gonads, as well as other endocrine tissues that may be potentially affected by MCZ. MCZ exposure was shown to interfere with thyroid functioning through impairment of thyroid hormone synthesis due to inhibition of sodium-iodine symporter (NIS) and thyroid peroxidase (TPO) activity, as well as thyroglobulin expression. Direct thyrotoxic effect may also contribute to thyroid pathology upon MCZ exposure. Gonadal effects of MCZ involve inhibition of sex steroid synthesis due to inhibition of P450scc (CYP11A1), as well as 3β-HSD and 17β-HSD. In parallel with altered hormone synthesis, MCZ was shown to down-regulate androgen and estrogen receptor signaling. Taken together, these gonad-specific effects result in development of both male and female reproductive dysfunction. In parallel with clearly estimated targets for MCZ endocrine disturbing activity, namely thyroid and gonads, other endocrine tissues may be also involved. Specifically, the fungicide was shown to affect cortisol synthesis that may be mediated by modulation of CYP11B1 activity. Moreover, MCZ exposure was shown to interfere with PPARγ signaling, being a key regulator of adipogenesis. The existing data also propose that endocrine-disrupting effects of MCZ exposure may be mediated by modulation of hypothalamus-pituitary-target axis. It is proposed that MCZ neurotoxicity may at least partially affect central mechanisms of endocrine system functioning. However, further studies are required to unravel the mechanisms of MCZ endocrine disrupting activity and overall toxicity.

Indexed as

adipose tissueadrenalmancozebovarytestesthyroid

Identifiers

PMID35990020
PMCPMC9390121
OpenAlexW4205568113

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.